Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal
Proton pump inhibitors (PPIs) are used for maintaining or improving gastric problems. Evidence from observational studies indicates that PPI therapy is associated with an increased risk of gastric cancer. However, the evidence for PPIs increasing the risk of gastric cancer is still being debated. Th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/13/3052 |
| _version_ | 1797480759138713600 |
|---|---|
| author | Tahmina Nasrin Poly Ming-Chin Lin Shabbir Syed-Abdul Chih-Wei Huang Hsuan-Chia Yang Yu-Chuan (Jack) Li |
| author_facet | Tahmina Nasrin Poly Ming-Chin Lin Shabbir Syed-Abdul Chih-Wei Huang Hsuan-Chia Yang Yu-Chuan (Jack) Li |
| author_sort | Tahmina Nasrin Poly |
| collection | DOAJ |
| description | Proton pump inhibitors (PPIs) are used for maintaining or improving gastric problems. Evidence from observational studies indicates that PPI therapy is associated with an increased risk of gastric cancer. However, the evidence for PPIs increasing the risk of gastric cancer is still being debated. Therefore, we aimed to investigate whether long-term PPI use is associated with an increased risk of gastric cancer. We systematically searched the relevant literature in electronic databases, including PubMed, EMBASE, Scopus, and Web of Science. The search and collection of eligible studies was between 1 January 2000 and 1 July 2021. Two independent authors were responsible for the study selection process, and they considered only observational studies that compared the risk of gastric cancer with PPI treatment. We extracted relevant information from selected studies, and assessed the quality using the Newcastle−Ottawa scale (NOS). Finally, we calculated overall risk ratios (RRs) with 95% confidence intervals (CIs) of gastric cancer in the group receiving PPI therapy and the control group. Thirteen observational studies, comprising 10,557 gastric cancer participants, were included. Compared with patients who did not take PPIs, the pooled RR for developing gastric cancer in patients receiving PPIs was 1.80 (95% CI, 1.46–2.22, <i>p</i> < 0.001). The overall risk of gastric cancer also increased in patients with gastroesophageal reflux disease (GERD), <i>H. pylori</i> treatment, and various adjusted factors. The findings were also consistent across several sensitivity analyses. PPI use is associated with an increased risk of gastric cancer in patients compared with those with no PPI treatment. The findings of this updated study could be used in making clinical decisions between physicians and patients about the initiation and continuation of PPI therapy, especially in patients at high risk of gastric cancer. Additionally, large randomized controlled trials are needed to determine whether PPIs are associated with a higher risk of gastric cancer. |
| first_indexed | 2024-03-09T22:04:42Z |
| format | Article |
| id | doaj.art-a25d345a79e74ac39a52227a4b33bae2 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:04:42Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a25d345a79e74ac39a52227a4b33bae22023-11-23T19:43:35ZengMDPI AGCancers2072-66942022-06-011413305210.3390/cancers14133052Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical AppraisalTahmina Nasrin Poly0Ming-Chin Lin1Shabbir Syed-Abdul2Chih-Wei Huang3Hsuan-Chia Yang4Yu-Chuan (Jack) Li5Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, TaiwanGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, TaiwanGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, TaiwanInternational Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei 110301, TaiwanGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, TaiwanGraduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 110301, TaiwanProton pump inhibitors (PPIs) are used for maintaining or improving gastric problems. Evidence from observational studies indicates that PPI therapy is associated with an increased risk of gastric cancer. However, the evidence for PPIs increasing the risk of gastric cancer is still being debated. Therefore, we aimed to investigate whether long-term PPI use is associated with an increased risk of gastric cancer. We systematically searched the relevant literature in electronic databases, including PubMed, EMBASE, Scopus, and Web of Science. The search and collection of eligible studies was between 1 January 2000 and 1 July 2021. Two independent authors were responsible for the study selection process, and they considered only observational studies that compared the risk of gastric cancer with PPI treatment. We extracted relevant information from selected studies, and assessed the quality using the Newcastle−Ottawa scale (NOS). Finally, we calculated overall risk ratios (RRs) with 95% confidence intervals (CIs) of gastric cancer in the group receiving PPI therapy and the control group. Thirteen observational studies, comprising 10,557 gastric cancer participants, were included. Compared with patients who did not take PPIs, the pooled RR for developing gastric cancer in patients receiving PPIs was 1.80 (95% CI, 1.46–2.22, <i>p</i> < 0.001). The overall risk of gastric cancer also increased in patients with gastroesophageal reflux disease (GERD), <i>H. pylori</i> treatment, and various adjusted factors. The findings were also consistent across several sensitivity analyses. PPI use is associated with an increased risk of gastric cancer in patients compared with those with no PPI treatment. The findings of this updated study could be used in making clinical decisions between physicians and patients about the initiation and continuation of PPI therapy, especially in patients at high risk of gastric cancer. Additionally, large randomized controlled trials are needed to determine whether PPIs are associated with a higher risk of gastric cancer.https://www.mdpi.com/2072-6694/14/13/3052proton pump inhibitorsgastric cancerstomach neoplasmsepidemiologymeta-analysis |
| spellingShingle | Tahmina Nasrin Poly Ming-Chin Lin Shabbir Syed-Abdul Chih-Wei Huang Hsuan-Chia Yang Yu-Chuan (Jack) Li Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal Cancers proton pump inhibitors gastric cancer stomach neoplasms epidemiology meta-analysis |
| title | Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal |
| title_full | Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal |
| title_fullStr | Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal |
| title_full_unstemmed | Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal |
| title_short | Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal |
| title_sort | proton pump inhibitor use and risk of gastric cancer current evidence from epidemiological studies and critical appraisal |
| topic | proton pump inhibitors gastric cancer stomach neoplasms epidemiology meta-analysis |
| url | https://www.mdpi.com/2072-6694/14/13/3052 |
| work_keys_str_mv | AT tahminanasrinpoly protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal AT mingchinlin protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal AT shabbirsyedabdul protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal AT chihweihuang protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal AT hsuanchiayang protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal AT yuchuanjackli protonpumpinhibitoruseandriskofgastriccancercurrentevidencefromepidemiologicalstudiesandcriticalappraisal |